CTD-ILD

Clinical trials for CTD-ILD explained in plain language.

Never miss a new study

Get alerted when new CTD-ILD trials appear

Sign up with your email to follow new studies for CTD-ILD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug aims to slow lung scarring in autoimmune patients

Disease control Not yet recruiting

This study tests a drug called telitacicept in 260 adults with connective tissue diseases like lupus or rheumatoid arthritis that have caused lung scarring. The goal is to see if it can slow the loss of lung function compared to a placebo, when added to standard treatments. Parti…

Matched conditions: CTD-ILD

Phase: PHASE3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control

Last updated May 07, 2026 18:38 UTC

CTD-ILD

Get alerted when new CTD-ILD trials appear

New drug aims to slow lung scarring in autoimmune patients